Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Almirall ( (ES:ALM) ) has provided an announcement.
Almirall released a brief financial results and business update document for fiscal year 2025, dated February 23, 2026, intended solely for use during a company presentation. The company stresses that the material is a summarized Spanish translation of an English version available on its website and may not be disclosed or reused without prior written consent.
The release emphasizes that past share price or security performance data cannot be relied upon as an indicator of future results, and that the document contains forward-looking information based on internal estimates and external sources not independently verified. Almirall also clarifies that the document is not an offer or solicitation to buy, sell, or subscribe for securities in any jurisdiction, underscoring its purely informational and non‑transactional nature for stakeholders and investors.
The most recent analyst rating on (ES:ALM) stock is a Hold with a EUR14.00 price target. To see the full list of analyst forecasts on Almirall stock, see the ES:ALM Stock Forecast page.
More about Almirall
Almirall is a pharmaceutical company focused on developing and commercializing medicines. The group operates in prescription and specialist therapies, with a particular emphasis on dermatology and related medical conditions in international markets.
Average Trading Volume: 200,021
Technical Sentiment Signal: Buy
Current Market Cap: €2.97B
For an in-depth examination of ALM stock, go to TipRanks’ Overview page.